Clinical Evaluation of Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Peripheral Blood Recovery after Allogeneic Bone Marrow Transplantation in Children with Malignant Disorders.

DOI

Bibliographic Information

Other Title
  • 小児悪性腫よう患児に対する同種骨髄移植後の末梢血回復に及ぼすｇｒａｎｕｌｏｃｙｔｅ　ｃｏｌｏｎｙ‐ｓｔｉｍｕｌａｔｉｎｇ　ｆａｃｔｏｒの影響

Search this article

Description

We analyzed the clinical effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in allogeneic bone marrow transplanted children. The median period required for neutrophil recovery (> 500/μl) was markedly shortened by the rhG-CSF treatment : 21 days in the rhG-CSF group (n=11) versus 27 days in the historical control group (n=12). We found no effects on recovery of other blood cell series. However, the mean neutrophil counts and frequency of neutropenic patients at day 11 and day 15 after BMT were not significantly different in both groups. These results suggest that rhG-CSF does not contribute to neutrophil recovery in very early posttransplant period. It may be necessary to evaluate further on ideal time for starting rhG-CSF in children who undergo allogeneic bone marrow transplantation.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390282679318483328
  • NII Article ID
    130004346257
  • DOI
    10.11412/jjph1987.8.23
  • ISSN
    18844723
    09138706
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top